Abstract: Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and to combat resistant bacterial strains. Compounds and pharmaceutical compositions containing these compounds are described, and are based on a generic scaffold structure. Synthetic methods and methods of using the compounds also are described. Preferred compound 6jc48-1 ((E)-2,4-bis(4-bromophenyl)-6-(4-(dimethyl-amino)styryl)pyrylium boron tetrafluoride salt) binds to Lipid II with high affinity, has markedly reduced cytotoxicity than BAS00127538, and retains activity against drug-resistant strains of Enterococci. It is stable in plasma, has dramatically improved pharmacokinetic and pharmacodynamics properties, and possesses in vivo efficacy in a mouse model of sepsis.

Abstract: Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and to combat resistant bacterial strains. Compounds and pharmaceutical compositions containing these compounds are described, and are based on a genetic scaffold structure. Synthetic methods and methods of using the compounds also are described. Preferred compounds bind to Lipid II with high affinity, have markedly reduced cytotoxicity compared to BAS00127538, and retain activity against drug-resistant strains of Enterococci. They are stable in plasma, have dramatically improved pharmacokinetic and pharmacodynamics properties, and possess in vivo efficacy in a mouse model of sepsis.

Abstract: Compounds that inhibit Myeloid Cell Leukemia-1 (Mcl-1) oncoprotein, and methods of using the same, are provided for treating disease.

Abstract: Compounds that inhibit p38? MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

Abstract: Mcl-1 selective inhibitors, Bcl-2 selective inhibitors, and Mcl-1/Bcl-2 dual inhibitors and methods of using the same for the treatment of disease are disclosed.

Abstract: The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nanomolar inhibition of cell survival in AML cells. Preferred compounds contained an aziridine or a secondary amino alcohol pharmacophore.

Abstract: A pendulum pump includes a housing, a cover positioned on the housing and forming a cavity therebetween, an inner rotor and an outer rotor positioned within the cavity, wherein the inner rotor is connected via a plurality of pendulums to the outer rotor, and the pendulums are mounted to the outer rotor in an articulated manner such that a rotational eccentricity can be imparted between the inner rotor and the outer rotor to control a flow rate of the pendulum pump, and a protective plate positioned within the cavity and against a surface of one of the housing and the cover.

Abstract: Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and to combat resistant bacterial strains. Compounds and pharmaceutical compositions containing these compounds are described, and are based on a generic scaffold structure. Synthetic methods and methods of using the compounds also are described. Preferred compounds bind to Lipid II with high affinity, have markedly reduced cytotoxicity compared to BAS00127538, and retain activity against drug-resistant strains of Enterococci. They are stable in plasma, have dramatically improved pharmacokinetic and pharmacodynamics properties, and possess in vivo efficacy in a mouse model of sepsis.

Abstract: An electrical fault detector is shown for installation in electrical network (101) of the type comprising a first voltage source (104) and a second voltage source (107), each of which have a respective positive rail (105,108) connected by a positive concentrator (110) and a respective negative rail (106,109) connected by a negative concentrator (111). The detector comprises an inductor (112) for location in one of: the positive concentrator between the connections of the positive rails thereto, and the negative concentrator between the connections of the negative rails to thereto. The detector also comprises a fault identification device (113) configured to monitor the voltage across the inductor, and generate a fault signal in response to the voltage across the inductor exceeding a threshold.

Abstract: Compounds, pharmaceutical compositions, and methods for reversing fosfomycin resistance are disclosed. Embodiments of the disclosed compounds inhibit fosfomycin-inhibiting enzymes. Some embodiments of the compounds are FosA inhibitors. The disclosed pharmaceutical compositions include (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) a compound, or a pharmaceutically acceptable salt thereof, which inhibits a fosfomycin-inhibiting enzyme. A method of inhibiting growth of a fosfomycin-resistant bacterium includes contacting the bacterium with (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) an effective amount of a disclosed compound or a pharmaceutically acceptable salt thereof.

Abstract: Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and to combat resistant bacterial strains. Compounds and pharmaceutical compositions containing these compounds are described, and are based on a generic scaffold structure. Synthetic methods and methods of using the compounds also are described. Preferred compound 6jc48-1 ((E)-2,4-bis(4-bromophenyl)-6-(4-(dimethyl-amino)styryl)pyrylium boron tetrafluoride salt) binds to Lipid II with high affinity, has markedly reduced cytotoxicity than BAS00127538, and retains activity against drug-resistant strains of Enterococci. It is stable in plasma, has dramatically improved pharmacokinetic and pharmacodynamics properties, and possesses in vivo efficacy in a mouse model of sepsis.

Abstract: Compounds that inhibit Myeloid Cell Leukemia-1 (Mcl-1) oncoprotein, and methods of using the same, are provided for treating disease.

Abstract: An electrical fault detector is shown for installation in electrical network (101) of the type comprising a first voltage source (104) and a second voltage source (107), each of which have a respective positive rail (105,108) connected by a positive concentrator (110) and a respective negative rail (106,109) connected by a negative concentrator (111). The detector comprises an inductor (112) for location in one of: the positive concentrator between the connections of the positive rails thereto, and the negative concentrator between the connections of the negative rails to thereto. The detector also comprises a fault identification device (113) configured to monitor the voltage across the inductor, and generate a fault signal in response to the voltage across the inductor exceeding a threshold.

Abstract: A method of determining the location of a fault within a first inductive part of an electrical circuit, including a voltage source, first inductive part and second inductive part. A shortened circuit created by the fault includes the voltage source, a portion of the first inductive part and the second, connected in series. The fault occurs across first and second points in the first inductive part. The length of first inductive part between a positive terminal and first point is substantially equal to the length of first inductive part between a negative terminal and second point. The voltage source supplies a known voltage Vs when the fault occurs and the second inductive part has a known inductance L2 when the fault occurs. The method takes advantage of the initial transient response of the circuit to determine the inductance of the portion of the first inductive part in the shortened circuit.

Abstract: A method of determining the location of a fault within a first inductive part of an electrical circuit, including a voltage source, first inductive part and second inductive part. A shortened circuit created by the fault includes the voltage source, a portion of the first inductive part and the second, connected in series. The fault occurs across first and second points in the first inductive part. The length of first inductive part between a positive terminal and first point is substantially equal to the length of first inductive part between a negative terminal and second point. The voltage source supplies a known voltage Vs when the fault occurs and the second inductive part has a known inductance L2 when the fault occurs. The method takes advantage of the initial transient response of the circuit to determine the inductance of the portion of the first inductive part in the shortened circuit.

Abstract: The present invention relates compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell comprise contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell. The compounds exhibit increased inhibitory activity against c-Myc relative to the known c-Myc inhibitor small-molecule benzofurazan N-([1,1?-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine (10074-G5).

Abstract: A compound, having the formula A-1: Wherein R1 and R2 are defined herein. Methods of using the compound and compositions containing the compound are provided.

Abstract: Small-molecule scaffolds based on 1,2-diphenylacetylene that accurately replicate the spatial and angular projections of several side chains on both faces of an ?-helix, specifically the i and i+7 side chains on one face, and the i and i+2 side chains on the other. The amphipathic ?-helix mimetic can be used to disrupt disease-promoting protein-protein interactions that are mediated by ?-helices.

Abstract: The present invention relates compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell comprise contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell. The compounds exhibit increased inhibitory activity against c-Myc relative to the known c-Myc inhibitor small-molecule benzofurazan N-([1,1?-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine (10074-G5).

Abstract: Small-molecule scaffolds based on 1,2-diphenylacetylene that accurately replicate the spatial and angular projections of several side chains on both faces of an ?-helix, specifically the i and i+7 side chains on one face, and the i and i+2 side chains on the other. The amphipathic ?-helix mimetic can be used to disrupt disease-promoting protein-protein interactions that are mediated by ?-helices.